Tfh细胞相关因子CXCL-13在小细胞肺癌中的作用及临床意义

doi:10.3877/cma.j.issn.1674-6902.2017.02.013

目的

探讨Tfh细胞的趋化因子CXCL-13与SCLC发病及进展的相关性。

方法

随机收集28例SCLC患者(SCLC组)和38例健康人(对照组)的临床资料和外周血样本，采用ELISA法检测小细胞肺癌(SCLC)患者外周血中滤泡性辅助性T细胞(follicular helper T cells, Tfh)的趋化因子CXC基元配体-13(chemokine C-X-C motif ligand-13, CXCL-13)表达水平，结合临床资料按照性别、年龄、吸烟情况及肿瘤分期进行亚组分析，明确各相关因素与SCLC的关系。

结果

SCLC组CXCL-13(55.36±5.293)ng/L明显高于对照组(28.71±2.671)ng/L，P<0.0001；在SCLC组中年龄、性别及吸烟史差异对CXCL-13表达没有显著差异：男性(53.52±5.759) ng/L、女(64.59±14.08) ng/L，P＝0.4995；年龄<55岁(50.08±6.945)ng/L、年龄≥55岁(58.01±7.184) ng/L，P＝0.4347;吸烟<200年支(62.59±8.975) ng/L、吸烟≥200年支(68.09±4.128) ng/L，P＝0.5854。而在SCLC组与对照组的对比中，各因素对CXCL-13的表达均有一定的影响，女性(9.976±1.534 ng/L，64.59±14.08 ng/L，P＝0.0028)，男性(31.07±3.778 ng/L，53.52±5.759 ng/L，P＝0.0023)；年龄<55岁(27.77±2.987 ng/L，50.08±6.945 ng/L，P＝0.0121)，年龄≥55岁(31.75±6.096 ng/L，58.01±7.184 ng/L，P＝0.01)；吸烟<200年支(28.15±2.723 ng/L，62.59±8.975 ng/L，P＝0.0028)；吸烟≥200年支(28.86±7.312 ng/L，68.09±4.128 ng/L，P＝0.0005)。SCLC组中，不同肿瘤分期的CXCL-13表达有显著差异，(31.07±2.37 ng/L，57.18±5.919 ng/L，P＝0.0003)。

结论

在SCLC患者的外周静脉血中CXCL-13的表达水平与健康对照组有显著差异，且与性别、年龄、吸烟情况有密切关系，同时肿瘤分期越晚的患者，其CXCL-13的表达水平越高。CXCL-13作为Tfh的趋化因子，对SCLC的早期临床诊断和预后判断有潜在的临床意义。

关键词: 小细胞肺癌, CXCL-13, Tfh, 临床意义

Objective

To detect expression levels of follicular helper T cells (follicular helper T cells, Tfh) chemokine C-X-C motif ligand-13 (CXCL-13) in small cell lung cancer (SCLC) patients and healthy human peripheral blood, to investigate the interaction between Tfh cells chemokine CXCL-13 and SCLC in the pathogenesis and progression.

Methods

It was randomly collected that the clinical data and peripheral blood samples of 28 cases of SCLC patients (SCLC group) and 38 healthy people (control group), Tfh cell chemokine CXCL-13 was detected by ELISA assay in peripheral blood, combined with clinical data, according to gender, age, smoking status and tumor stage subgroup analysis, clear the relationship between the related factors and SCLC.

Results

SCLC group CXCL-13 (55.36±5.293) ng/L was significantly higher than the control group (28.71±2.671 ng/L), P<0.0001; in the SCLC group, age, sex and smoking history differences on the expression of CXCL-13 had no significant difference: male(53.52 ± 5.759) ng/L, female (64.59 ± 14.08) ng/L, P=0.4995; aged <55 years old (50.08±6.945)ng/L, aged≥55 years old (58.01±7.184)ng/L, P=0.4347; smoking<200 years (62.59±8.975)ng/L, smoking≥200 years (68.09±4.128)ng/L, P=0.5854. And in contrast to the SCLC group and the control group, the influencing factors on CXCL-13 expression were female (9.976±1.534, 64.59±14.08 ng/L, P=0.0028), male (31.07±3.778 ng/L, 53.52±5.759 ng/L, P=0.0023); age<55 (27.77±2.987 ng/L, 50.08±6.945 ng/L, P=0.0121), aged≥55 years old (31.75±6.096 ng/L, 58.01±7.184 ng/L, P=0.01); smoking<200 years (28.15±2.723 ng/L, 62.59±8.975 ng/L, P=0.0028); smoking≥200 years (28.86±7.312 ng/L, 68.09±4.128 ng/L, P=0.0005). In the SCLC group, the expression of CXCL-13 in different tumor stage had significant difference(31.07±2.37 ng/L, 57.18±5.919 ng/L, P=0.0003).

Conclusions

The expression level of CXCL-13 in patients with SCLC in peripheral blood were significantly different from those of the healthy control group, and gender, age, smoking status are closely related, and the later stage of tumor patients, the CXCL-13 expression level is higher. CXCL-13, as a chemokine of Tfh, has potential clinical significance in early diagnosis and prognosis of SCLC.

Key words: Small cell lung cancer, CXCL-13, Tfh, Clinical significance

图1 SCLC组和健康对照组的CXCL-13的表达水平的比较

图2 SCLC组与健康对照组各亚组CXCL-13表达水平的比较

图3 CXCL-13的表达与肺癌分期的关系

表1 不同肿瘤分期病人两两检验P值表

Ⅰ	Ⅱ	Ⅲ	Ⅳ	?
Ⅰ	－	－	－	－
Ⅱ	－	－	0.8535	0.2365
Ⅲ	－	0.8535	－	0.1086
Ⅳ	－	0.2365	0.1086	－

表1 不同肿瘤分期病人两两检验P值表

Ⅰ	Ⅱ	Ⅲ	Ⅳ	?
Ⅰ	－	－	－	－
Ⅱ	－	－	0.8535	0.2365
Ⅲ	－	0.8535	－	0.1086
Ⅳ	－	0.2365	0.1086	－

图4 SCLC患者中各亚组CXCL-13的表达

1	任成山，白莉，钱桂生. 慢性阻塞性肺疾病合并肺癌临床特征及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(2): 137-142.
2	王会中，任成山，金发光. 肿瘤生物标志物在肺癌患者检测中的临床意义及研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2016, 9(3): 329-333.
3	Lawrence RE, Salgia R, MET molecular mechanisms and therapies in lung cancer[J]. Cell Adh Migr, 2010, 4(1): 146-152.
4	Liang Y, Tian B, Zhang J, et al. Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer[J]. Int J Nanomedicine, 2017, 12: 1699-1715.
5	Hamilton G, Rath B, Ulsperger E. How to target small cell lung cancer[J]. Oncoscience, 2015, 2(8): 684-692.
6	Zhou T, Hong S, Hu Z, et al. A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer[J]. Tumour Biol, 2015, 36(1): 337-343.
7	Saavedra D, Garcia B, Lage A. T cell subpopulations in healthy elderly and lung cancer patients: Insights from cuban studies[J]. Front Immunol, 2017, 8: 146.
8	Johnston RJ, Poholek AC, DiToro D, et al. Bcl6 and blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation[J]. Science, 2009, 325(5943): 1006-1010.
9	Ma CS, Suryani S, Avery DT, et al. Early commitment of naive human CD4(＋) T cells to the T follicular helper (T(FH)) cell lineage is induced by IL-12[J]. Immunol Cell Biol, 2009, 87(8): 590-600.
10	Akiba H, Takeda K, Kojima Y, et al. The role of ICOS in the CXCR5＋ follicular B helper T cell maintenance in vivo[J]. J Immunol, 2005, 175(4): 2340-2348.
11	Rasheed AU, Rahn HP, Sallusto F, et al. Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression[J]. Eur J Immunol, 2006, 36(7): 1892-1903.
12	Bauquet AT, Jin H, Paterson AM, et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells[J]. Nat Immunol, 2009, 10(2): 167-175.
13	Pangault C, Amé-Thomas P, Ruminy P, et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis[J]. Leukemia, 2010, 24(12): 2080-2089.
14	Ito T, Hanabuchi S, Wang YH, et al. Two functional subsets of FOXP3＋ regulatory T cells in human thymus and periphery[J]. Immunity, 2008, 28(6): 870-880.
15	Shi W, Li X, Cha Z, et al. Dysregulation of circulating follicular helper T cells in nonsmall cell lung cancer[J]. DNA Cell Biol, 2014, 33(6): 355-360.
16	Zhou DM, Xu YX, Zhang LY, et al. The role of follicular T helper cells in patients with malignant lymphoid disease[J]. Hematology, 2017, doi: 10.1080/10245332.2017.1300623.
17	Ma QY, Huang DY, Zhang HJ, et al. Function of follicular helper T cell is impaired and correlates with survival time in non-small cell lung cancer[J]. Int Immunopharmacol, 2016, 41: 1-7.
18	Hamilton G, Rath B, Smoking. inflammation and small cell lung cancer: recent developments[J]. Wien Med Wochenschr, 2015, 165(19-20): 379-386.
19	Sheng SY, Gu Y, Lu CG, et al. The distribution and function of human memory T cell subsets in lung cancer[J]. Immunol Res, 2017, doi: 10.1007/s12026-016-8882-y.
20	Jiang W, Zhang W, Wu L, et al. MicroRNA-related polymorphisms in PI3K/Akt/mTOR pathway genes are predictive of limited-disease small cell lung cancer treatment outcomes[J]. Biomed Res Int, 2017, 2017: 6501385.
21	Chen L, Huang Z, Yao G, et al. Erratum to: The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer[J]. J Transl Med, 2016, 14(1): 318.
22	Hui W, Zhao C, Bourgoin SG. LPA Promotes T cell recruitment through synthesis of CXCL13[J]. Mediators Inflamm, 2015, 2015: 248492.
23	Yuan F, Si-Ning C, Ji-Hong Z, et al. Clinical study of lung-supplementing and stasis-dissolving decoction (Bufei Huayu Tang) combined with gefitnib for treatment of advanced non-small cell lung cancer[J]. Pak J Pharm Sci, 2016, 29(6(Special)): 2185-2189.
24	Morrison EJ, Novotny PJ, Sloan JA, et al. Emotional problems, quality of life, and symptom burden in patients with lung cancer[J]. Clin Lung Cancer, 2017, doi: 10.1016/j.cllc.2017.02.008.
25	Ferguson MK, Huisingh-Scheetz M, Thompson K, et al. The influence of physician and patient gender on risk assessment for lung cancer resection[J]. Ann Thorac Surg, 2017, doi: 10.1016/j.athoracsur.2017.01.066.
26	Zhou D, Tang W, Liu X, et al. Clinical verification of plasma messenger RNA as novel noninvasive biomarker identified through bioinformatics analysis for lung cancer[J]. Oncotarget, 2017 ，doi: 10.18632/oncotarget.16701.
27	Zhao F, Zhou Y, Ge PF, et al. A prediction model for lymph node metastases using pathologic features in patients intraoperatively diagnosed as stage I non－small cell lung cancer[J]. BMC Cancer, 2017, 17(1): 267.
28	Sateia HF, Choi Y, Stewart RW, et al. Screening for lung cancer[J]. Semin Oncol, 2017, 44(1): 74-82.

[1]	赵蒙蒙, 黄洁, 余荣环, 王葆青. 过表达小GTP酶Rab32抑制非小细胞肺癌细胞侵袭性生长[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 512-518.
[2]	张桂萍, 丘勇林, 湛绮婷, 孙乐栋. 晚期非小细胞肺癌血清Ape1/Ref-1对放射性肺损伤发生的预测意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 519-523.
[3]	韩晓宇, 李柯育, 赵志菲, 高建平. SNHG17过表达对非小细胞肺癌切除术预后的意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 543-547.
[4]	刘松, 张进召, 贾艳云. 帕博利珠单抗治疗晚期非小细胞肺癌反应降低与抗生素预处理的关系[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 553-557.
[5]	李多, 郝昭昭, 陈延伟, 南岩东. 血清PTX3表达与非小细胞肺癌骨转移的相关性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 558-562.
[6]	陈旭, 牛凯, 孙建国. 放疗联合免疫治疗对驱动基因阴性NSCLC的困惑分析及应对策略[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 341-348.
[7]	杨静, 附舰, 康艳霞. 血浆ctDNA T790M突变和总代谢肿瘤体积对晚期EGFR突变NSCLC患者TKIs治疗及预后意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 379-384.
[8]	赵海燕, 靳海涛, 孔莺, 何瑞远. 血浆NGS-ctDNA对EGFR-TKIs治疗晚期NSCLC患者的预后意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 385-391.
[9]	韩苏驰, 黄琰菁. 乳酸脱氢酶与小细胞肺癌脑转移风险临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 402-406.
[10]	白丽丽, 江榆, 黄亮亮, 白莹, 张敏. 作业疗法在非小细胞肺癌患者术后康复中应用分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 411-415.
[11]	李静静, 许金花, 吴国峰, 任亚俊, 张骞云. 伏美替尼一线治疗EGFR突变晚期NSCLC脑转移的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 426-429.
[12]	尹炳驿, 张楚楚, 刘艺, 林洪生. 益气清金汤加味治疗晚期非小细胞肺癌的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 462-465.
[13]	罗孝平, 封敏, 黄川, 唐茜, 蒋艳, 胡莉丽. 渐进式抗阻训练干预在非小细胞肺癌中的临床应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 472-474.
[14]	张迅夫, 马金山, 蒋云龙, 加纳提·托勒恒, 侯昌剑, 萨伍提·斯拉吉丁. GATA3在非小细胞肺癌组织中的表达及临床病理意义[J]. 中华胸部外科电子杂志, 2024, 11(03): 175-179.
[15]	李子健, 王锐, 钟云鹏, 张迪轩, 梁韵娟, 杨超, 何建行, 李树本. 自体肺移植术在胸部恶性肿瘤中的临床应用[J]. 中华胸部外科电子杂志, 2024, 11(03): 193-200.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Role and clinical significance of Tfh cell associated factor CXCL-13 in the pathogenesis of small cell lung cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Role and clinical significance of Tfh cell associated factor CXCL-13 in the pathogenesis of small cell lung cancer